In vivo haemostatic effects of activated prothrombin complex concentrate and recombinant factor VIIa in a haemophilia A patient with inhibitors.
Grossmann
R
R
Central Laboratory, Blood Coagulation Unit, Institute of Clinical Biochemistry and Pathobiochemistry, University of Wuerzburg, Germany. r.grossmann@medizin.uni-wuerzburg.de
Geisen
U
U
Walter
U
U
D000368:Aged; D015415:Biomarkers / Q000097:blood; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000494:pharmacology / Q000592:standards*; D001780:Blood Coagulation Tests; D016903:Drug Monitoring; D005167:Factor VII / Q000008:administration & dosage / Q000494:pharmacology / Q000592:standards*; D015942:Factor VIIa; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006470:Hemorrhage / Q000517:prevention & control; D006487:Hemostasis / Q000187:drug effects*; D006490:Hemostatics / Q000008:administration & dosage / Q000494:pharmacology / Q000592:standards*; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D007700:Kinetics; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000592:standards*
D015415:Biomarkers; D001779:Blood Coagulation Factors; D006490:Hemostatics; D007518:Isoantibodies; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa